請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47121完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 康照洲(Jaw-Jou Kang) | |
| dc.contributor.author | Po-Lin Liao | en |
| dc.contributor.author | 廖伯霖 | zh_TW |
| dc.date.accessioned | 2021-06-15T05:48:11Z | - |
| dc.date.available | 2015-09-09 | |
| dc.date.copyright | 2010-09-09 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-08-19 | |
| dc.identifier.citation | Addis PB. 1986. Occurrence of lipid oxidation products in foods. Food Chem Toxicol 24(10-11):1021-30.
Allen LB, Capps BE, Miller EC, Clemmons DR, Maile LA. 2009. Glucose-oxidized low-density lipoproteins enhance insulin-like growth factor I-stimulated smooth muscle cell proliferation by inhibiting integrin-associated protein cleavage. Endocrinology 150(3):1321-9. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. 1994. Structure of the human cyclo-oxygenase-2 gene. Biochem J 302 ( Pt 3):723-7. Ares MP, Porn-Ares MI, Moses S, Thyberg J, Juntti-Berggren L, Berggren P, Hultgardh-Nilsson A, Kallin B, Nilsson J. 2000. 7beta-hydroxycholesterol induces Ca(2+) oscillations, MAP kinase activation and apoptosis in human aortic smooth muscle cells. Atherosclerosis 153(1):23-35. Ares MP, Porn-Ares MI, Thyberg J, Juntti-Berggren L, Berggren PO, Diczfalusy U, Kallin B, Bjorkhem I, Orrenius S, Nilsson J. 1997. Ca2+ channel blockers verapamil and nifedipine inhibit apoptosis induced by 25-hydroxycholesterol in human aortic smooth muscle cells. J Lipid Res 38(10):2049-61. Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. 1999. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc Biol 19(8):1819-24. Auge N, Garcia V, Maupas-Schwalm F, Levade T, Salvayre R, Negre-Salvayre A. 2002. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol 22(12):1990-5. Auge N, Maupas-Schwalm F, Elbaz M, Thiers JC, Waysbort A, Itohara S, Krell HW, Salvayre R, Negre-Salvayre A. 2004. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 110(5):571-8. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. 2004. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 42(2):121-31. Berk BC. 2001. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 81(3):999-1030. Berliner JA, Heinecke JW. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20(5):707-27. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. 1995. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91(9):2488-96. Bjorkhem I, Diczfalusy U. 2002. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 22(5):734-42. Boissonneault GA, Hennig B, Wang Y, Ouyang CM, Krahulik K, Cunnup L, Oeltgen PR. 1991. Effect of oxysterol-enriched low-density lipoprotein on endothelial barrier function in culture. Low-density lipoproteins. Ann Nutr Metab 35(4):226-32. Bonetti PO, Lerman LO, Lerman A. 2003. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23(2):168-75. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. 1995. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82(3):405-14. Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, Moncada S. 1993. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 342(8867):338-40. Brash AR. 2001. Arachidonic acid as a bioactive molecule. J Clin Invest 107(11):1339-45. Brown AJ, Jessup W. 1999. Oxysterols and atherosclerosis. Atherosclerosis 142(1):1-28. Brown AJ, Leong SL, Dean RT, Jessup W. 1997. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res 38(9):1730-45. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. 2005. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39(3):443-52. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47(4):943-6. Carpenter G, Cohen S. 1990. Epidermal growth factor. J Biol Chem 265(14):7709-12. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. 2001. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 167(5):2831-8. Chen CN, Li YS, Yeh YT, Lee PL, Usami S, Chien S, Chiu JJ. 2006. Synergistic roles of platelet-derived growth factor-BB and interleukin-1beta in phenotypic modulation of human aortic smooth muscle cells. Proc Natl Acad Sci U S A 103(8):2665-70. Cheng D, Chang CC, Qu X, Chang TY. 1995. Activation of acyl-coenzyme A:cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system. J Biol Chem 270(2):685-95. Cheng J, Cui R, Chen CH, Du J. 2007. Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology 148(5):2085-94. Cheng YW, Kang JJ, Shih YL, Lo YL, Wang CF. 2005. Cholesterol-3-beta, 5-alpha, 6-beta-triol induced genotoxicity through reactive oxygen species formation. Food Chem Toxicol 43(4):617-22. Cherepanova OA, Pidkovka NA, Sarmento OF, Yoshida T, Gan Q, Adiguzel E, Bendeck MP, Berliner J, Leitinger N, Owens GK. 2009. Oxidized phospholipids induce type VIII collagen expression and vascular smooth muscle cell migration. Circ Res 104(5):609-18. Chiu JJ, Usami S, Chien S. 2009. Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann Med 41(1):19-28. Choi SH, Aid S, Bosetti F. 2009. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 30(4):174-81. Christ M, Luu B, Mejia JE, Moosbrugger I, Bischoff P. 1993. Apoptosis induced by oxysterols in murine lymphoma cells and in normal thymocytes. Immunology 78(3):455-60. Christopherson KS, Bredt DS. 1997. Nitric oxide in excitable tissues: physiological roles and disease. J Clin Invest 100(10):2424-9. Cipollone F. 2005. COX-2 and prostaglandins in atherosclerosis. Lupus 14(9):756-9. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V and others. 2001. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104(8):921-7. Clancy RM, Abramson SB. 1995. Nitric oxide: a novel mediator of inflammation. Proc Soc Exp Biol Med 210(2):93-101. Clare K, Hardwick SJ, Carpenter KL, Weeratunge N, Mitchinson MJ. 1995. Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis 118(1):67-75. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. 2006. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 12(9):1075-80. Colles SM, Maxson JM, Carlson SG, Chisolm GM. 2001. Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. Trends Cardiovasc Med 11(3-4):131-8. Cybulsky MI, Gimbrone MA, Jr. 1991. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251(4995):788-91. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS. 2001. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107(10):1255-62. Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, Garcia-Cardena G, Gimbrone MA, Jr. 2004. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci U S A 101(41):14871-6. Deckert V, Persegol L, Viens L, Lizard G, Athias A, Lallemant C, Gambert P, Lagrost L. 1997. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 95(3):723-31. Desideri G, Ferri C. 2005. Endothelial activation. Sliding door to atherosclerosis. Curr Pharm Des 11(17):2163-75. Di Rosa M, Ialenti A, Ianaro A, Sautebin L. 1996. Interaction between nitric oxide and cyclooxygenase pathways. Prostaglandins Leukot Essent Fatty Acids 54(4):229-38. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736):601-5. Edwards PA, Ericsson J. 1998. Signaling molecules derived from the cholesterol biosynthetic pathway: mechanisms of action and possible roles in human disease. Curr Opin Lipidol 9(5):433-40. Eligini S, Habib A, Lebret M, Creminon C, Levy-Toledano S, Maclouf J. 2001. Induction of cyclo-oxygenase-2 in human endothelial cells by SIN-1 in the absence of prostaglandin production. Br J Pharmacol 133(7):1163-71. Estrada CR, Adam RM, Eaton SH, Bagli DJ, Freeman MR. 2006. Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder. Lab Invest 86(12):1293-302. Falk E. 1996. [Plaque vulnerability and disruption]. Rev Clin Esp 196(4 Monografico):6-12. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105(8):1049-56. Furchgott RF, Zawadzki JV. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373-6. Galis ZS, Khatri JJ. 2002. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251-62. Go YM, Levonen AL, Moellering D, Ramachandran A, Patel RP, Jo H, Darley-Usmar VM. 2001. Endothelial NOS-dependent activation of c-Jun NH(2)- terminal kinase by oxidized low-density lipoprotein. Am J Physiol Heart Circ Physiol 281(6):H2705-13. Gordon DJ, Rifkind BM. 1989. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med 321(19):1311-6. Guan Z, Buckman SY, Miller BW, Springer LD, Morrison AR. 1998. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem 273(44):28670-6. Guardiola F, Codony R, Addis PB, Rafecas M, Boatella J. 1996. Biological effects of oxysterols: current status. Food Chem Toxicol 34(2):193-211. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. 1995. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 147(2):267-77. Hansson GK, Libby P, Schonbeck U, Yan ZQ. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91(4):281-91. Hisamoto K, Ohmichi M, Kanda Y, Adachi K, Nishio Y, Hayakawa J, Mabuchi S, Takahashi K, Tasaka K, Miyamoto Y and others. 2001. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 276(50):47642-9. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. 2007. Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 45(4):849-57. Hodis HN, Crawford DW, Sevanian A. 1991. Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: further evidence for the role of cholesterol oxidation in atherosclerosis. Atherosclerosis 89(2-3):117-26. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. 1993. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 75(7):1273-86. Hubbard RW, Ono Y, Sanchez A. 1989. Atherogenic effect of oxidized products of cholesterol. Prog Food Nutr Sci 13(1):17-44. Hughes H, Mathews B, Lenz ML, Guyton JR. 1994. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb 14(7):1177-85. Ikeda U, Shimada K. 2003. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 26(2):55-9. Imai H, Werthessen NT, Subramanyam V, LeQuesne PW, Soloway AH, Kanisawa M. 1980. Angiotoxicity of oxygenated sterols and possible precursors. Science 207(4431):651-3. Ioannou YA. 2001. Multidrug permeases and subcellular cholesterol transport. Nat Rev Mol Cell Biol 2(9):657-68. Jaffe EA, Nachman RL, Becker CG, Minick CR. 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52(11):2745-56. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. 2003. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284(1):31-53. Kashles O, Szapary D, Bellot F, Ullrich A, Schlessinger J, Schmidt A. 1988. Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions. Proc Natl Acad Sci U S A 85(24):9567-71. Kavurma MM, Khachigian LM. 2003. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 89(2):289-300. Keller JN, Hanni KB, Kindy MS. 2000. Oxidized high-density lipoprotein induces neuron death. Exp Neurol 161(2):621-30. Kodali R, Hajjou M, Berman AB, Bansal MB, Zhang S, Pan JJ, Schecter AD. 2006. Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res 69(3):706-15. Kotani J, Mintz GS, Castagna MT, Berzingi CO, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R, Weissman NJ. 2003. Relation of plaque morphology to thrombolysis in myocardial infarction flow in acute myocardial infarction determined by intravascular ultrasound. Am J Cardiol 91(9):1096-9. Krut LH, Yang JW, Schonfeld G, Ostlund RE, Jr. 1997. The effect of oxidizing cholesterol on gastrointestinal absorption, plasma clearance, tissue distribution, and processing by endothelial cells. Arterioscler Thromb Vasc Biol 17(4):778-85. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H and others. 1999. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 100(12):1280-4. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M. 2004. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. Faseb J 18(2):300-10. Lange Y, Ye J, Strebel F. 1995. Movement of 25-hydroxycholesterol from the plasma membrane to the rough endoplasmic reticulum in cultured hepatoma cells. J Lipid Res 36(5):1092-7. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. 2004. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286(4):H1416-24. Leitinger N. 2003. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 14(5):421-30. Lepoivre M, Fieschi F, Coves J, Thelander L, Fontecave M. 1991. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun 179(1):442-8. Li CH, Tzeng SL, Cheng YW, Kang JJ. 2005. Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem 280(28):26193-9. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. 2007. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology 148(7):3356-63. Liebmann C. 2001. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 13(11):777-85. Lim KH, Ancrile BB, Kashatus DF, Counter CM. 2008. Tumour maintenance is mediated by eNOS. Nature 452(7187):646-9. Liu P, Sun M, Sader S. 2006. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol 22 Suppl B:25B-30B. Lizard G, Gueldry S, Sordet O, Monier S, Athias A, Miguet C, Bessede G, Lemaire S, Solary E, Gambert P. 1998. Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J 12(15):1651-63. Lordan S, Mackrill JJ, O'Brien NM. 2008. Involvement of Fas signalling in 7beta-hydroxycholesterol-and cholesterol-5beta,6beta-epoxide-induced apoptosis. Int J Toxicol 27(3):279-85. Lusis AJ. 2000. Atherosclerosis. Nature 407(6801):233-41. MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15:323-50. Maraschiello C, Esteve E, Garcia Regueiro JA. 1998. Cholesterol oxidation in meat from chickens fed alpha-tocopherol- and beta-carotene-supplemented diets with different unsaturation grades. Lipids 33(7):705-13. Martinet W, Schrijvers DM, Timmermans JP, Bult H. 2008. Interactions between cell death induced by statins and 7-ketocholesterol in rabbit aorta smooth muscle cells. Br J Pharmacol 154(6):1236-46. Mehta D, Malik AB. 2006. Signaling mechanisms regulating endothelial permeability. Physiol Rev 86(1):279-367. Michel T, Feron O. 1997. Nitric oxide synthases: which, where, how, and why? J Clin Invest 100(9):2146-52. Moriki T, Maruyama H, Maruyama IN. 2001. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 311(5):1011-26. Murray CJ, Lopez AD. 1997. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349(9063):1436-42. Murray SW, Palmer ND. 2009. Intravascular ultrasound and virtual histology interpretation of plaque rupture and thrombus in acute coronary syndromes. Heart 95(18):1494. N'Guessan PD, Etouem MO, Schmeck B, Hocke AC, Scharf S, Vardarova K, Opitz B, Flieger A, Suttorp N, Hippenstiel S. 2007. Legionella pneumophila-induced PKCalpha-, MAPK-, and NF-kappaB-dependent COX-2 expression in human lung epithelium. Am J Physiol Lung Cell Mol Physiol 292(1):L267-77. Nagayama K, Matsumoto T. 2008. Contribution of actin filaments and microtubules to quasi-in situ tensile properties and internal force balance of cultured smooth muscle cells on a substrate. Am J Physiol Cell Physiol 295(6):C1569-78. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. 1998. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 18(5):842-51. Nathan C, Xie QW. 1994. Nitric oxide synthases: roles, tolls, and controls. Cell 78(6):915-8. Nedelec E, Abid A, Cipolletta C, Presle N, Terlain B, Netter P, Jouzeau J. 2001. Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism. Biochem Pharmacol 61(8):965-78. Netzel-Arnett S, Mallya SK, Nagase H, Birkedal-Hansen H, Van Wart HE. 1991. Continuously recording fluorescent assays optimized for five human matrix metalloproteinases. Anal Biochem 195(1):86-92. Nishio E, Watanabe Y. 1996. Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation. Biochem Biophys Res Commun 226(3):928-34. Ohshima H, Bartsch H. 1994. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 305(2):253-64. Ohtani K, Miyabara K, Okamoto E, Kamei M, Matsui-Yuasa I. 1996. Cytotoxicity of 7-ketocholesterol toward cultured rat hepatocytes and the effect of vitamin E. Biosci Biotechnol Biochem 60(12):1989-93. Owens GK. 1995. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75(3):487-517. Page-McCaw A, Ewald AJ, Werb Z. 2007. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8(3):221-33. Patti G, Melfi R, Di Sciascio G. 2005. [The role of endothelial dysfunction in the pathogenesis and in clinical practice of atherosclerosis. Current evidences]. Recenti Prog Med 96(10):499-507. Peng SK, Taylor CB, Hill JC, Morin RJ. 1985. Cholesterol oxidation derivatives and arterial endothelial damage. Atherosclerosis 54(2):121-33. Peng SK, Tham P, Taylor CB, Mikkelson B. 1979. Cytotoxicity of oxidation derivatives of cholesterol on cultured aortic smooth muscle cells and their effect on cholesterol biosynthesis. Am J Clin Nutr 32(5):1033-42. Pettus BJ, Chalfant CE, Hannun YA. 2002. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 1585(2-3):114-25. Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA, Thomas JA, Leitinger N, Owens GK. 2007. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res 101(8):792-801. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI. 1994. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A 91(4):1500-4. Ramasamy S, Boissonneault GA, Hennig B. 1992. Oxysterol-induced endothelial cell dysfunction in culture. J Am Coll Nutr 11(5):532-8. Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D, Lampland AL and others. 2001. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 71(1):1-20. Renault MA, Jalvy S, Belloc I, Pasquet S, Sena S, Olive M, Desgranges C, Gadeau AP. 2003. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circ Res 93(7):674-81. Riedel H, Dull TJ, Honegger AM, Schlessinger J, Ullrich A. 1989. Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors. EMBO J 8(10):2943-54. Rimner A, Al Makdessi S, Sweidan H, Wischhusen J, Rabenstein B, Shatat K, Mayer P, Spyridopoulos I. 2005. Relevance and mechanism of oxysterol stereospecifity in coronary artery disease. Free Radic Biol Med 38(4):535-44. Ross R. 1999. Atherosclerosis is an inflammatory disease. Am Heart J 138(5 Pt 2):S419-20. Roy Chowdhury SK, Sangle GV, Xie X, Stelmack GL, Halayko AJ, Shen GX. 2009. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab. Ryan L, O'Callaghan YC, O'Brien NM. 2006. Involvement of calcium in 7beta -hydroxycholesterol and cholesterol-5beta,6beta -epoxide-induced apoptosis. Int J Toxicol 25(1):35-9. Salonen JT, Nyyssonen K, Salonen R, Porkkala-Sarataho E, Tuomainen TP, Diczfalusy U, Bjorkhem I. 1997. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 95(4):840-5. Schmeck B, N'Guessan PD, Ollomang M, Lorenz J, Zahlten J, Opitz B, Flieger A, Suttorp N, Hippenstiel S. 2007. Legionella pneumophila-induced NF-kappaB- and MAPK-dependent cytokine release by lung epithelial cells. Eur Respir J 29(1):25-33. Schmeck B, Zahlten J, Moog K, van Laak V, Huber S, Hocke AC, Opitz B, Hoffmann E, Kracht M, Zerrahn J and others. 2004. Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem 279(51):53241-7. Schmidt HH, Walter U. 1994. NO at work. Cell 78(6):919-25. Schroepfer GJ, Jr. 2000. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev 80(1):361-554. Schwartz BG, Economides C, Mayeda GS, Burstein S, Kloner RA. The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. Int J Impot Res 22(2):77-90. Schwartz SM, Benditt EP. 1976. Clustering of replicating cells in aortic endothelium. Proc Natl Acad Sci U S A 73(2):651-3. Sevanian A, Peterson AR. 1986. The cytotoxic and mutagenic properties of cholesterol oxidation products. Food Chem Toxicol 24(10-11):1103-10. Seye CI, Knaapen MW, Daret D, Desgranges C, Herman AG, Kockx MM, Bult H. 2004. 7-Ketocholesterol induces reversible cytochrome c release in smooth muscle cells in absence of mitochondrial swelling. Cardiovasc Res 64(1):144-53. Shah PK. 2009. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 23(1):31-40. Simionescu M, Antohe F. 2006. Functional ultrastructure of the vascular endothelium: changes in various pathologies. Handb Exp Pharmacol(176 Pt 1):41-69. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417(6890):750-4. Smith WL, Langenbach R. 2001. Why there are two cyclooxygenase isozymes. J Clin Invest 107(12):1491-5. Spiegel S, Milstien S. 2003. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4(5):397-407. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T and others. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386(6622):292-6. Thim T, Hagensen MK, Bentzon JF, Falk E. 2008. From vulnerable plaque to atherothrombosis. J Intern Med 263(5):506-16. Tsai CS, Loh SH, Liu JC, Lin JW, Chen YL, Chen CH, Cheng TH. 2009. Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Atherosclerosis 206(1):86-94. Tuomainen TP, Diczfalusy U, Kaikkonen J, Nyyssonen K, Salonen JT. 2003. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med 35(8):922-8. Ullrich A, Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61(2):203-12. Ushio-Fukai M. 2009. Vascular signaling through G protein-coupled receptors: new concepts. Curr Opin Nephrol Hypertens 18(2):153-9. Van der Heyden MA, Nievers M, Verkleij AJ, Boonstra J, Van Bergen en Henegouwen PM. 1997. Identification of an intracellular domain of the EGF receptor required for high-affinity binding of EGF. FEBS Lett 410(2-3):265-8. Vanhoutte PM. 2009. COX-1 and vascular disease. Clin Pharmacol Ther 86(2):212-5. Vassalle C, Domenici C, Lubrano V, L'Abbate A. 2003. Interaction between nitric oxide and cyclooxygenase pathways in endothelial cells. J Vasc Res 40(5):491-9. Vatassery GT, Quach HT, Smith WE, Krick TP, Ungar F. 1997a. Analysis of hydroxy and keto cholesterols in oxidized brain synaptosomes. Lipids 32(1):101-7. Vatassery GT, Quach HT, Smith WE, Ungar F. 1997b. Oxidation of cholesterol in synaptosomes and mitochondria isolated from rat brains. Lipids 32(8):879-86. Voisin L, Foisy S, Giasson E, Lambert C, Moreau P, Meloche S. 2002. EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. Am J Physiol Cell Physiol 283(2):C446-55. Wang D, Paria BC, Zhang Q, Karpurapu M, Li Q, Gerthoffer WT, Nakaoka Y, Rao GN. 2009. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injury-induced restenosis. Circ Res 104(9):1066-75. Wang DQ, Afdhal NH. 2001. Good cholesterol, bad cholesterol: role of oxysterols in biliary tract diseases. Gastroenterology 121(1):216-8. Watanabe N, Ikeda U. 2004. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 6(2):112-20. Wells A. 1999. EGF receptor. Int J Biochem Cell Biol 31(6):637-43. Witztum JL, Steinberg D. 2001. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 11(3-4):93-102. Wolozin B, Brown J, 3rd, Theisler C, Silberman S. 2004. The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 10(2):127-46. Xu Q. 2007. Progenitor cells in vascular repair. Curr Opin Lipidol 18(5):534-9. Xu Q. 2009. Disturbed flow-enhanced endothelial turnover in atherosclerosis. Trends Cardiovasc Med 19(6):191-5. Yadav PN, Liu Z, Rafi MM. 2003. A diarylheptanoid from lesser galangal (Alpinia officinarum) inhibits proinflammatory mediators via inhibition of mitogen-activated protein kinase, p44/42, and transcription factor nuclear factor-kappa B. J Pharmacol Exp Ther 305(3):925-31. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84(4):1086-95. Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ. 2004. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 39(3):732-8. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. 2004. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 95(10):989-97. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47121 | - |
| dc.description.abstract | 氧化性低密度脂蛋白會改變脂蛋白的代謝；影響黏滯性分子，生長因子，細胞素等基因的表現；以及造成細胞程序性死亡，細胞移動和細胞增生。因此氧化性低密度脂蛋白被認為與血管動脈粥狀硬化的發生有密切的關聯性，而氧化性的膽固醇則是氧化性低密度脂蛋白的主要組成物質，在過去的研究中也指出，較高濃度之氧化性膽固醇類物質會傷害血管內皮細胞、血管平滑肌細胞、免疫細胞等，並出現微核或核酸片斷化等細胞凋亡指標，同時也觀察到粒線體的異常變化。在動脈硬化病灶形成的過程中，內皮細胞的活化，平滑肌細胞的移行與增生皆扮演了重要的角色。因此，在本項研究當中，我們探討了常見三種氧化性膽固醇7-ketocholesterol (7-keto), Cholesterol-5α, 6α-epoxide (α-poxide)及Cholesterol 3β，5α，6β-triol (α-triol)，在人類臍靜脈內皮細胞與大鼠平滑肌細胞所扮演的角色。 結果顯示，α-triol會調控人類臍靜脈內皮細胞當中調控環氧化酶-2 (COX-2) mRNA與蛋白的表現並且進而釋放出前列腺素E2 (PGE2)。此外，α-triol會造成人類臍靜脈內皮細胞當中eNOS1177蛋白的磷酸化而觀察到一氧化氮(NO)的產生。在探討其分子機制上，前處理p38蛋白與PI3K蛋白的抑制劑會抑制α-triol於人類臍靜脈內皮細胞當中所觀察到eNOS1177蛋白的磷酸化，而NO，PI3K，p38與NF-κB的抑制劑則有效地防止了α-triol在人類臍靜脈內皮細胞當中所促進的COX-2 mRNA與蛋白之增加。另外，7-keto與α-poxide會促進大鼠平滑肌的移行與增生。透過抑制劑的處理，我們證實了MMPs, EGFR 與PI3K會參予在7-keto與α-poxide所造成的平滑肌移行，而EGFR，PI3K，ERK以及sphingomyelin的水解在促進7-keto與α-poxide所造成的平滑肌增生中扮演了重要的角色。進一步透過共免疫沉澱法，我們發現7-keto與α-poxide會造成平滑肌中EGFR的磷酸化並與PI3K結合。利用RT-PCR，西方點墨法與酵素螢光受質，我們證實了7-keto與α-poxide會在平滑肌細胞內造成Akt與ERK的活化，並造成MMP-2/9 mRNA與酵素活性的增加。綜合以上的結果，我們證明了這三種常見的氧化性膽固醇對於促進動脈硬化的發生扮演了重要的角色。 | zh_TW |
| dc.description.abstract | Oxidized LDLs (oxLDLs), may induce changes in lipoprotein metabolism, gene expression of adhesion molecules, growth factors, and cytokines, cell viability/apoptosis, migration, and proliferation. There are strong correlation between atherosclerosis and ox-LDL. Oxysterols is the major components of ox-LDL. The cytotoxicity of oxysterol has been widely reported in endothelial cells, smooth muscle cells and macrophages concomitant mitochondria dysfunction and nuclear fragmentation which are the apoptotic marker. The formation of an atherosclerotic lesion occurs through several cellular events that include endothelial cell activation, vascular smooth muscle cell migration and proliferation. Therefore, we investigated the roles of three common oxysterols, cholesterol 3β，5α，6β-triol (α-triol), 7-ketocholesterol (7-keto) and cholesterol-5α,6α-epoxide (α-epoxide) on human umbilical vein endothelial cells (HUVECs) and smooth muscle cells (SMCs). We found that α-triol dose- and time-dependently enhanced COX-2 protein expression and mRNA production followed by PGE2 generation in HUVECs. In addition, α-triol upregulated peNOS1177 protein phosphorylation and dose-dependently increased nitric oxide production. In studying the mechanisms involved in α-Triol-induced COX2/PGE2 production, eNOS1177 phosphorylation was abrogated by the p38 and PI3K inhibitor. Inhibitors of NO, PI3K, p38, and NF-κB, effectively attenuated COX-2 protein induction and mRNA expression, suggesting that the PI3K-Akt-eNOS pathway, p38MAPK, and NF-κB are involved in α-triol-induced COX-2 expression. Also, our results showed that 7-keto and α-epoxide promoted SMC migration by a chemotactic assay, and induced mitogenic effects by MTT assay and BrdU assay. Specific inhibitors confirmed that MMPs, EGFR and PI3K are involved in oxysterol-induced SMC migration, while EGFR, ERK, Akt, and sphingomyelin/ceramide pathways might play a role in SMC proliferation. More, the co-immunoprecipitation study indicated that 7-keto and α-epoxide caused EGFR phosphorylation and there was an interaction between EGFR and PI3K. At protein expression level, Akt and ERK were activated, at messenger RNA level, MMP-2/9 mRNA was transcribed, at enzyme activity level, the MMP-2/9 enzyme activity were increased in SMCs treated with 7-keto and α-epoxide according to Western bolt, RT-PCR and a fluorogenic substrate. Taken together, we concluded that 7-keto and α-epoxide may be an atherogenic factor. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T05:48:11Z (GMT). No. of bitstreams: 1 ntu-99-F93447003-1.pdf: 5817862 bytes, checksum: 457789a1bdbe2705f563d0d6c33acb62 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 口試委員會審定書………………………………………………………………. II
誌謝………………………………………………………………………………. III 中文摘要…………………………………………………………………………. XI 英文摘要…………………………………………………………………………. XIII 第一章 背景介紹………………………………………………………………... 1 1-1 動脈粥狀硬化 (atherosclerosis)…………………………………………….. 2 1-2 氧化性膽固醇 (oxysterols)…………………………………………………. 4 1-3 氧化性膽固醇的不良反應………………………………………………….. 5 1-4 血管內皮細胞與動脈粥狀硬化的關係…………………………………….. 7 1-4-1: 血管內皮細胞(endothelial cells)…………………………………………. 7 1-4-2: 環氧化酶(cyclooxygenase)..……………………………………………... 8 1-4-3: 一氧化氮與一氧化氮合成酶 (NO and NOS)………………………….. 9 1-5: 血管平滑肌細胞與動脈硬化的關係………………………………………. 12 1-5-1: 血管平滑肌細胞 (smooth muscle cells; SMCs)…………………………. 12 1-5-2: 上皮生長因子受體 (epidermal growth factor receptorl EGFR)………… 13 1-5-3: 基質金屬蛋白酶(Matrix metalloproteinases; MMPs)…………………… 15 1-6 : 研究動機與目的…………………………………………………………… 17 第二章: 實驗材料與方法……………………………………………………….. 23 2-1 實驗材料…………………………………………………………………….. 24 2-1-1 實驗藥品…………………………………………………………………... 24 2-1-2 抗體與試劑………………………………………………………………... 25 2.2. 細胞培養……………………………………………………………………. 25 2.2.1人類臍帶靜脈內皮細胞 (HUVECs)之初級細胞培養……………………. 25 2.2.2大鼠胸主動脈血管平滑肌細胞 (SMCs)之初級細胞培養……………….. 26 2.3. 細胞存活率測試(Cell viability test/ MTT assay)…………………………. 27 2.4 Bromodeoxyuridine (BrdU) 標記測試 (BudU incorporation assay)……….. 27 2.5. 前列腺素E2之濃度測定(PGE2 assay)……………………………………... 28 2.6. 一氧化氮生成量的偵測 (NO determination)……………………………… 29 2.7. 西方點墨法 (Western blot analysis)………………………………………... 30 2.8. 反轉錄聚合酶鏈鎖反應(Reverse Transcription Polymerase Chain Reaction, RT-PCR)………………………………………………………………... 31 2.9 鞘脂類脂值之含量偵測(sphingolipid quantification)…………………….. 32 2.10 細胞移行試驗 (Cell migration assay)……………………………………... 33 2.11 MMP蛋白活性之偵測 (Determination of MMP activity)…………………. 33 2.12 免疫沉澱法(immunoprecipitation)………………………………………… 34 2.14. 細胞內活性氧物質 (intracellular reactive oxygen species; ROS)之測定.. 35 2.13. 統計分析(Statistic analysis)……………………………………………….. 36 第3-1章 Cholesterol-3-beta,5-alpha,6-beta-triol induced PI3K-Akt-eNOS-dependent cyclooxygenase-2 expression in endothelial cells….. 39 前言……………………………………………………………………40 結果……………………………………………………………………42 討論……………………………………………………………………50 圖集……………………………………………………………………53 第3-2章 7-Ketocholesterol and cholesterol-5α,6α-epoxide induce smooth muscle cell migration and proliferation through the Epidermal Growth Factor Receptor/Phosphoinositide 3-Kinase/Akt signaling pathways……….. 66 前言………………………………………………………………67 結果……………………………………………………………………69 討論………………………………………………………………………76 圖集………………………………………………………………………81 第四章 結論……………………………………………………………100 第五章 參考文獻………………………………………………………104 附錄…………………………………………………………………123 | |
| dc.language.iso | zh-TW | |
| dc.subject | 氧化性膽固醇 | zh_TW |
| dc.subject | 動脈粥狀硬化 | zh_TW |
| dc.subject | 環氧化酶 | zh_TW |
| dc.subject | 上皮生長因子受體 | zh_TW |
| dc.subject | 人類臍帶靜脈內皮細胞 | zh_TW |
| dc.subject | 血管平滑肌細胞 | zh_TW |
| dc.subject | smooth muscle cells | en |
| dc.subject | epidermal growth factor receptor | en |
| dc.subject | cyclooxygenase-2 | en |
| dc.subject | atherosclerosis | en |
| dc.subject | oxysterols | en |
| dc.subject | human umbilical vein endothelial cells | en |
| dc.title | 氧化性膽固醇在動脈硬化中的角色探討 | zh_TW |
| dc.title | Effects of Oxysterols on Atherosclerosis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 鄭幼文(Yu-Wen Cheng),顏茂雄(Mao-Hsiung Yen),蘇銘嘉(Ming-Jai Su),彭福佐(Fu-Chuo Peng) | |
| dc.subject.keyword | 氧化性膽固醇,動脈粥狀硬化,環氧化酶,-2,上皮生長因子受體,人類臍帶靜脈內皮細胞,血管平滑肌細胞, | zh_TW |
| dc.subject.keyword | oxysterols,atherosclerosis,cyclooxygenase-2,epidermal growth factor receptor,human umbilical vein endothelial cells,smooth muscle cells, | en |
| dc.relation.page | 123 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2010-08-19 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 毒理學研究所 | zh_TW |
| 顯示於系所單位： | 毒理學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 未授權公開取用 | 5.68 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。